Frontotemporal lobar degeneration because of mutations in the progranulin (PGRN) gene presents a high variability both in the clinical phenotype and age of onset of disease. Factors that influence this variability remain largely unknown. The aim of our study was to determine whether selected genetic variables modify age at onset of disease in our series of 21 patients with a single splicing mutation (c.709-1G>A) in the PGRN gene, all of whom were of Basque descent. In our analysis, we included the following genetic variables: PGRN rs5848 and rs9897526 polymorphisms, APOE and microtubule-associated protein tau genotypes, and PRNP codon 129 polymorphism. We found no association between PGRN polymorphisms, APOE and microtubule-associated protein tau genotypes, and age at onset of the disease; whereas we report evidence for an association between PRNP codon 129 polymorphism and age at onset of disease in frontotemporal dementia-PGRN( +) patients. MM homozygous carriers presented onset of disease on average 8.5 years earlier than patients who carried at least 1 valine on their PRNP codon 129 (MV or VV). The biological justification for this association remains speculative.
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Genetic or environmental factors that influence the phenotypic variability and the age at onset remain unknown. Of the genetic factors studied, the haplotype of microtubuleassociated protein tau (MAPT) seems to have no effect on the age at onset, 1,2 although 1 recent study has shown that H1H2 subjects carrying the Leu271LeufsX10 mutation in PGRN had an earlier disease onset than H2H2 individuals. 3 The presence of at least 1 APOE e4 allele has been associated with a delay in onset in some studies, 1, 4 but not in others. 2 One international study found that patients with the Arg493X mutation that carried the A-allele at rs9897526, a polymorphism on their wild-type PGRN allele, have delayed symptom onset. 2 Although homozygosity for the T-allele at rs5848 could act as a risk factor for frontotemporal dementia (FTD), no effect of this common genetic variant as a modifier factor in PGRN mutation carriers has been proved. 2 Our group identified the c.709-1G>A (Ala237Trpfsx4) mutation in the PGRN gene in patients with FTD. 5, 6 The objective of this study was to determine the potential role of some selected genetic factors in the age at onset of the disease in our series of patients with this single splicing mutation in PGRN. We included PRNP codon 129 analysis in our study because this polymorphism has been suggested as a possible disease-modifying factor in various neurodegenerative diseases.
METHODS

Study Population
Patients were recruited from the "Cognitive Disorders Unit" at Donostia Hospital, a tertiary referral center. We included patients with the c.709-1G>A mutation in PGRN. All patients were diagnosed with a FTD complex syndrome and were of Basque origin. The clinical and neuropsychologic features of the series have been published earlier. 5, 6 We considered age at onset as being when principal caregivers reported having observed the first symptoms of disease in a detailed interview. 
Genotyping
Statistical Analysis
Categorical variables are described by absolute and relative frequencies and compared with the w 2 test. The Pearson correlation coefficient was used to study the linear association between continuous variables, and, for each group considered, the normal distribution of such variables was checked using the Shapiro-Wilks test. Analysis of variance test, or the Welch test as required, was used to analyze mean equalities. The Kernel density estimator was used to estimate the probability function. P values lower than 0.05 were considered significant. Statistical analysis was performed using R statistical software, version R 2.6.1.
RESULTS
Twenty-one patients with the c.709-1G>A mutation from 13 families were included in the genetic analysis. Fourteen were women and 7 men and their age at onset of disease ranged from 42 to 70 years (mean±SD=59.2±7.2 y). This variable showed a fairly symmetrical distribution with a median of 61 years. No significant difference was found in the age at onset between men and women (men 57.4±6.8 y vs. women 60.1±7.5 y, P=0.432) or between different initial diagnostic groups (P=0.22).
The distribution of the studied polymorphisms and haplotypes is summarized in Table 1 . Age at onset of dementia was not associated with the rs5848 (P=0.591) or the rs9897526 (P=0.654) polymorphisms of the PGRN gene; neither was age at onset affected by MAPT genotype nor APOE status when we compared the group that carried at least 1 APOE e4 allele with other APOE variants (APOE e4 carriers, 61±7.4 y vs. APOE e4 noncarriers, 59.9±6.2 y, P=0.756).
Analyses with the analysis of variance test showed significant differences among the 3 groups of patients classified according to their PRNP codon 129 status (MM, MV, and VV, P=0.043). Specifically, the MV and VV groups were comparable regarding age at onset of disease (MV 61.7±6.28 y vs. VV 61.7±5.85 y). Given these results, we compared the group of patients who had at least 1 valine on their PRNP codon 129 (MV and VV) with the MM group. The MM homozygous patients, on average, were found to present 8.5 years earlier than patients who carried at least 1 valine on their PRNP codon 129 (MM 53.2±7.11 y vs. MV-VV 61.7±5.9 y, P=0.011) (Fig. 1 ).
DISCUSSION
Clinical descriptions of FTD-PGRN(+) patients show significant variability in the age at onset of the disease. Our study included patients with a single mutation in the PGRN gene (c.709-1G>A) and all patients were of Basque descent, with a homogeneous genetic background.
In this article, we report the influence of the PRNP codon 129 status on the age at onset of FTD because of PGRN haploinsufficiency. We observed an earlier age at onset of the disease for the PRNP codon 129 MM homozygous group. No significant differences were found between PRNP codon 129 distribution in our patients and in a sample of 119 Basque healthy subjects (MM: 40.3%, MV: 47.1%, and VV: 12.6%, P>0.05, data not published). The pathogenic mechanism that connects this polymorphism and some degenerative diseases like Alzheimer disease or primary progressive aphasia may reflect a general response to cellular stress rather than specific cooperation in aggregation of other proteins. 9 The function of the cellular prion protein is uncertain, although it has been implicated in several potential functions, including intracellular transport of copper, cellular resistance to oxidative stress, or normal synaptic functioning. A relationship between TAR-DNA binding protein-43, the main constituent of frontotemporal lobar degeneration-PGRN(+) associated ubiquitin-positive inclusions, and prion protein aggregates in human prion diseases has not been shown. 10 Our study has a number of limitations; one of them is the small sample size. Although our sample is relatively large, taking into account the prevalence of the disease and the inclusion of only patients carrying a single mutation in PGRN, it could be argued that it is too small to establish statistically robust differences. However, the estimated statistical power of our study is 0.763, close to the usually recommended 0.8 value in most study designs. We tried to replicate our finding in a sample of 54 patients with a clinical diagnosis of FTD, but we did not find significant influence of codon 129 polymorphism on the age at onset of disease (data not shown). These results are not surprising as this is a heterogeneous sample based on clinical diagnosis. Codon 129 PRNP influence could be undermined by the stronger influence of other genetic or environmental factors in a group of patients with probably different subjacent pathologic diseases.
Our findings warrant further replication in larger FTD-PGRN(+) series to avoid any spurious associations. An international effort should be encouraged to bring together patients into international cooperative studies.
